The use of a single daily dose of tadalafil to treat signs and symptoms of benign prostatic hyperplasia and erectile dysfunction.

Abstract

A strong and independent association between lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH) and erectile dysfunction (ED) has been widely evidenced in several clinical epidemiologic studies. Preclinical animal models have provided a great deal of information on potential common pathogenic mechanisms underlying these two clinical identities. Although the efficacy of the most commonly used treatments for LUTS/BPH is well defined, the negative impact of these treatments on sexual function - in particular, on ED - has triggered the search for new treatment options. In this regard, a new role for phosphodiesterase type 5 inhibitors in the treatment of LUTS/BPH and ED has been claimed. Tadalafil is one of the most extensively investigated phosphodiesterase type 5 inhibitors for this new indication. All evidence reported to date suggests that tadalafil 5 mg once daily is a safe and effective treatment option for both LUTS/BPH and ED.

• Authors: Mauro Gacci, Matteo Salvi, Arcangelo Sebastianelli, Linda Vignozzi, Giovanni Corona, Kevin T McVary, Steven A Kaplan, Mario Maggi, Marco Carini, Matthias Oelke
• Journal: Research and reports in urology (Res Rep Urol) Vol. 5 Pg. 99-111 (Apr 06 2013) ISSN: 2253-2447 [Print] England
• PMID: 24400241 (Publication Type: Journal Article)